Interaction software in a pharmacy flags dozens of alerts a day. Most are minor. The skill lies in recognising the few that can cause real harm and acting on them quickly.
These are five interactions I watch for closely in my work as a community pharmacist in Switzerland, with the mechanism behind each and what I do when I see them.
1. Simvastatin and clarithromycin
Mechanism: Clarithromycin strongly inhibits CYP3A4, the main enzyme that breaks down simvastatin (Neuvonen et al., 2006). Statin levels can rise many times over.
Risk: Muscle damage, ranging from pain to rhabdomyolysis, which can cause kidney failure (Patel et al., 2013). The combination is contraindicated.
What I do: I contact the prescriber to suggest an antibiotic without strong CYP3A4 inhibition, such as azithromycin, or a temporary pause of the statin during the antibiotic course. I explain to the patient which muscle symptoms should prompt them to seek help.
2. Vitamin K antagonists with NSAIDs or antibiotics
Mechanism: Phenprocoumon and acenocoumarol, still widely used in Switzerland, have a narrow therapeutic range. NSAIDs add bleeding risk by affecting platelets and the stomach lining. Several antibiotics raise the INR by changing metabolism or gut flora (Holbrook et al., 2005).
Risk: Gastrointestinal and other serious bleeding (Battistella et al., 2005).
What I do: This one often appears at the self-medication counter, when a patient on an anticoagulant asks for ibuprofen. I recommend paracetamol instead, at an appropriate dose. When an antibiotic is prescribed, I remind the patient to arrange an extra INR check.
3. The "triple whammy": ACE inhibitor or ARB, diuretic and NSAID
Mechanism: Each drug reduces kidney perfusion in a different way. Together, they can push vulnerable patients into acute kidney injury (Lapi et al., 2013). With a potassium-sparing diuretic such as spironolactone, hyperkalaemia is an added risk.
Risk: Acute kidney injury, especially in older patients or during dehydration, such as a gastrointestinal infection or hot weather.
What I do: I avoid recommending NSAIDs to these patients and explain why. For patients at high risk, I discuss "sick day rules" with the prescriber: which medicines to pause temporarily during vomiting, diarrhoea or fever.
4. QT-prolonging combinations
Mechanism: Several common drugs prolong the QT interval, including citalopram and escitalopram, domperidone, some macrolides and some antipsychotics. Effects add up when they are combined (Roden, 2004).
Risk: Torsades de pointes, a dangerous ventricular arrhythmia. Risk rises with age, female sex, low potassium or magnesium, heart disease and high doses (Roden, 2004).
What I do: I check the patient's other QT-prolonging drugs and risk factors, including diuretics that lower potassium. If the combination is not essential, I suggest an alternative to the prescriber.
5. St John's wort and almost everything metabolised by CYP3A4
Mechanism: St John's wort induces CYP3A4 and the transporter P-glycoprotein (Henderson et al., 2002). Levels of many drugs fall, including oral contraceptives, some anticoagulants, immunosuppressants and antiretrovirals. It also adds serotonergic effects to antidepressants.
Risk: Treatment failure, such as an unintended pregnancy or transplant rejection, or serotonin syndrome when combined with SSRIs or tramadol (Henderson et al., 2002).
What I do: Patients often do not consider herbal products to be "medicines". I ask specifically about herbal remedies and supplements, and I record them in the medication file.
A method, not a memory test
No pharmacist can memorise every interaction. What matters is a consistent method:
- Is the interaction clinically relevant? Consider the severity, the evidence and the size of the effect.
- Is this patient at risk? Age, kidney and liver function, dose and duration all change the answer.
- Is there a safer alternative? A different drug, dose or timing often solves the problem.
- Who needs to know? The prescriber, the patient, or both.
- Is it documented? Every intervention is recorded in the patient's file.
This method guided my work at Amavita in Bülach, where patient counselling focused on medication safety, drug interactions and contraindications. Earlier, as a hospital pharmacist, I analysed dosages and therapeutic appropriateness with clinical teams, where the same principles applied to more complex regimens.
The industry perspective
Interaction knowledge is also central in drug development and regulatory affairs. Developers characterise how a new drug is metabolised and transported, and test the most relevant interactions in clinical studies. The ICH M12 guideline harmonises how these drug–drug interaction studies are designed and interpreted (International Council for Harmonisation [ICH], 2024).
The results feed into the interactions section of the product information, which pharmacists then rely on every day. When an interaction causes harm in practice, the resulting case reports can become safety signals that lead to updated product information.
Key takeaways
- A small number of interactions cause most serious harm; recognising them is a core safety skill.
- A consistent assessment method beats memorising lists.
- Interaction data run in a loop: from development studies to product information to practice and back through pharmacovigilance.
References
Battistella, M., Mamdami, M. M., Juurlink, D. N., Rabeneck, L., & Laupacis, A. (2005). Risk of upper gastrointestinal hemorrhage in warfarin users who use selective COX-2 inhibitors. Archives of Internal Medicine, 165(2), 189–192.
Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B., & Arlett, P. (2002). St John's wort (Hypericum perforatum): Drug interactions and clinical outcomes. British Journal of Clinical Pharmacology, 54(4), 349–356. https://doi.org/10.1046/j.1365-2125.2002.01683.x
Holbrook, A. M., Pereira, J. A., Labiris, R., McDonald, H., Douketis, J. D., Crowther, M., & Wells, P. S. (2005). Systematic overview of warfarin and its drug and food interactions. Archives of Internal Medicine, 165(10), 1095–1106.
International Council for Harmonisation. (2024). Drug interaction studies M12. https://www.ich.org
Lapi, F., Azoulay, L., Yin, H., Nessim, S. J., & Suissa, S. (2013). Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study. BMJ, 346, e8525. https://doi.org/10.1136/bmj.e8525
Neuvonen, P. J., Niemi, M., & Backman, J. T. (2006). Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clinical Pharmacology & Therapeutics, 80(6), 565–581. https://doi.org/10.1016/j.clpt.2006.09.003
Patel, A. M., Shariff, S., Bailey, D. G., Juurlink, D. N., Gandhi, S., Mamdani, M., Gomes, T., Fleet, J., Hwang, Y. J., & Garg, A. X. (2013). Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Annals of Internal Medicine, 158(12), 869–876.
Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10), 1013–1022. https://doi.org/10.1056/NEJMra032426
Member discussion